The event was jointly organised by major pharmaceutical and biotech companies, including MSD, Takeda, Eli Lilly, and Astellas, and evaluated participants based on technological innovation, commercialisation potential, and partnership opportunities.
As the grand prize winner, MediMabBio received a ¥3,000,000 award and was invited to participate in the upcoming SHIC 2025 conference in Boston, which will serve as a valuable opportunity to meet global investors and potential partners.
During the competition, MediMabBio presented its AI-driven immunotherapy platform focused on both oncology and autoimmune diseases. CEO Kang Yu-Hoi commented, “Winning Innovation Tiger 2025 confirms recognition of our technology and growth potential. Through SHIC, we aim to strengthen global partnerships and accelerate investor engagement.”